PACTR201403000794397已完成未知
A Phase I/IIa Clinical Trial of HIV-1 Vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and Ad35-GRIN in Combined Regimens in Healthy HIV-1/2-negative Adults in Nairobi.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 50 Year(s)（—）
- 性别
- All
入选标准
- •Healthy adults aged 18-50
- •Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
- •Written informed consent.
- •Willing to undergo HIV-1 testing, counselling and receive test results.
- •All female volunteers must be willing to undergo urine pregnancy tests
- •If sexually active using an effective method of contraception until at least 4 months after the last vaccination.
- •Willing to forgo donating blood during the study
排除标准
- •Any relevant abnormality including history of immunodeficiency or autoimmune disease, or use of medication that is clinically significant, within the previous 6 months. (Use of inhaled steroids for asthma or topical steroids for localized skin conditions will not exclude a volunteer.)
- •Any clinically significant medical condition that is considered progressive or would make the volunteer unsuitable for the study
- •Any of the following:
- •Haematology
- •Haemoglobin < 9.0 g/dl for women and <11.0 g/dl for men
- •Absolute Neutrophil Count (ANC) ¿ 1000 /mm3
- •Absolute Lymphocyte Count (ALC) ¿ 600 /mm3
- •Platelets ¿100,000 /mm3, ¿ 550,000 /mm3
- •Biochemistry
- •Creatinine > 1.3 x upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) > 2.5 x ULN
- •Alanine aminotransferase (ALT) > 2.5 x ULN
- •Protein = 2+ or more
- •Blood = 2+ or more (for women: before or after menses)
- •Confirmed HIV-1 or HIV-2 infection, hepatitis B, hepatitis C or untreated syphilis
- •If female, pregnant, planning a pregnancy up to 4 months after the last vaccination, or lactating
- •Receipt of live attenuated vaccine within +/- 60 days of vaccination with Investigational Medicinal Product (IMP)
- •Receipt of other vaccine within +/- 14 days of vaccination with the IMP
- •Receipt of blood transfusion or blood products within the previous 6 months
- •Participate in another IMP clinical trial within the previous 3 months or during this study
- •Receipt of any investigational HIV-1 vaccine within the previous 6 years
- •History of severe reactogenicity events after vaccination, or history of severe allergic reactions
- •Smallpox vaccination < 3 years ago
- •Major psychiatric illness < 3 years ago
- •Allergy or hypersensitivity to latex, chronic skin problems, or skin and subcutaneous tissue thickness > 40 mm in either deltoid region
- •Presence of an implantable device
- •Current use of any electronic stimulation device
- •Cardiac disease or a heart condition
- •History of syncope or fainting episode within 1 year
- •Seizure disorder or history of seizure
研究者
相似试验
进行中（未招募）
1 期
ot applicableHuman Immunodeficiency Virus (HIV) infectionMedDRA version: 20.1 Level: PT Classification code 10020161 Term: HIV infection System Organ Class: 10021881 - Infections and infestationsEUCTR2017-003081-27-FRInserm-ANRS192
进行中（未招募）
1 期
A Phase I/II randomised therapeutic HIV vaccine trial in individualswho started antiretrovirals during primary or chronic infectioHIV InfectionMedDRA version: 20.0Level: LLTClassification code 10020441Term: Human immunodeficiency virus infection, unspecifiedSystem Organ Class: 100000004862EUCTR2017-003081-27-ITINSERM-ANRS1
进行中（未招募）
1 期
A comparative clinical trial, with randomization, of a therapeutic vaccine against HIV in people on antiretroviral treatment who initiated such treatment during primary or chronic infection.Human Immunodeficiency Virus (HIV) infectionMedDRA version: 20.1 Level: PT Classification code 10020161 Term: HIV infection System Organ Class: 10021881 - Infections and infestationsEUCTR2017-003081-27-ESInserm-ANRS192
Unknown
不适用
A Phase I Study of Prime-Boost HIV Vaccine CombinationsHIV/AIDSPACTR201304000534302Janssen120
已完成
1 期
A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3HIV InfectionsNCT00000755National Institute of Allergy and Infectious Diseases (NIAID)168